CJC-1295 (without DAC) vs Ipamorelin

CJC-1295 (without DAC)

CJC-1295 without DAC (also known as Modified GRF 1-29 or Mod GRF) is a synthetic 29-amino acid peptide analogue of growth hormone-releasing hormone (GHRH) with four amino acid substitutions (positions 2, 8, 15, and 27) that confer resistance to DPP-IV enzymatic degradation. Its mechanism of action involves binding to GHRH receptors (GHRH-R) on anterior pituitary somatotroph cells, stimulating cAMP-mediated signaling that triggers growth hormone synthesis and secretion. The amino acid modifications extend the peptide's biological half-life from under 10 minutes (native GHRH) to approximately 30 minutes, enabling meaningful GH pulse amplification while still preserving physiological pulsatile release patterns. Research on this modified GHRH analogue demonstrates it produces GH elevations within 15-30 minutes of administration, with return to baseline within 2-3 hours, mimicking natural GH pulse kinetics. Studies suggest CJC-1295 without DAC may support skin thickness and collagen production through GH-mediated IGF-1 elevation (Ionescu and Bhatt, Growth Hormone and IGF Research). Compared to the DAC-conjugated version (CJC-1295 with DAC), the non-DAC form produces shorter, more discrete GH pulses rather than sustained 7-10 day GH elevation, which some research protocols prefer for mimicking physiological patterns. It is frequently paired with ghrelin mimetics like ipamorelin for synergistic effect. Store lyophilized powder at -20C; reconstitute with bacteriostatic water and refrigerate at 2-8C for up to 21 days. This peptide is studied by endocrinology research departments, anti-aging medicine laboratories, and body composition research centers investigating GHRH axis modulation.

Ipamorelin

Ipamorelin is a synthetic pentapeptide (Aib-His-D-2Nal-D-Phe-Lys-NH2) that acts as a selective agonist of the growth hormone secretagogue receptor (GHS-R1a/ghrelin receptor). Its mechanism involves binding the ghrelin receptor on anterior pituitary somatotrophs to trigger calcium influx and GH granule exocytosis. What distinguishes ipamorelin from earlier ghrelin mimetics is its remarkable selectivity: clinical studies by Raun et al. (European Journal of Endocrinology, 1998) demonstrated that ipamorelin stimulates GH release in a dose-dependent manner without significantly affecting cortisol, prolactin, FSH, LH, or TSH levels, even at high doses. This selectivity profile makes it one of the cleanest GH secretagogues available for research. In bone metabolism research, Anderson et al. (Bone, 2001) showed that ipamorelin administration in ovariectomized rat models increased bone mineral content and bone formation markers, suggesting anabolic effects on skeletal tissue independent of IGF-1 elevation. The peptide has also been studied in post-operative recovery models, where it demonstrated prokinetic effects on gastric motility. Compared to GHRP-6 and GHRP-2, which also activate the ghrelin receptor but additionally stimulate appetite and affect cortisol/prolactin levels, ipamorelin provides a more isolated GH response. Compared to hexarelin, another GHRP, ipamorelin shows less desensitization with repeated dosing. Store lyophilized powder at -20C; reconstitute with bacteriostatic water and refrigerate at 2-8C for up to 28 days. Ipamorelin is investigated by endocrinology labs, bone metabolism research centers, orthopedic research departments, and gastrointestinal motility researchers.

Frequently Asked Questions